Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Regencell Bioscience Holdings Ltd RGC

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.


NDAQ:RGC - Post by User

User Avatar Image
(0)
•••
  • sungrin1309X
Post by sungrin1309on Oct 13, 2022 6:45am
120 Views
Post# 35021543

Company CEO/Philanthropist buys back RGC shares

Company CEO/Philanthropist buys back RGC shares$RGC, a healthcare business that was targeted by shortsellers in Q2 22', is facing the full force of the company CEO.

According to the CEO's Schedule 13D filings with the SEC (US Securities and Exchange Commission), the CEO (Mr Au) spent $5.03 million of his own cash to buy ordinary shares on the open market between July 2021 and May 2022. Mr Au currently owns a total of 10,539,159 ordinary shares, accounting for nearly 81% of the company's total issued and outstanding ordinary shares.

The company's objective is to provide a natural treatment technique for neurocognitive disorders and degenerations, notably ADHD and ASD, as well as viral illnesses that impair people's immune systems, such as COVID-19.

Aside from RGC's approach to developing successful treatments for ADHD and ASD, Mr Au has also been involved in his own philanthropic project (within his own means) that aims to provide care to over 10,000 affected children with ADHD, ASD, and Covid-19, as well as those affected by financial difficulties. Mr Au's programme has already benefitted over 150 youngsters since its inception on April 16, 22.
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities